Five Big Legal Stories From 2022
Teva, Sandoz And Viatris All Featured Prominently In 2022’s Stand Out Cases
Executive Summary
Generics Bulletin looks back at a selection of the most significant legal stories from 2022, including a major victory in the UK on the Eliquis blood thinner giant and continued action on generic label carve outs, which has the potential to reverberate through the US industry.
You may also be interested in...
Long-Awaited Nationwide Opioid Settlement To Move Forward For Teva
Teva has all but two US states on board for its long-hoped-for nationwide settlement to resolve opioid-related claims against the firm.
Alvotech And Teva File US Stelara Rival Ahead Of 2023 Expiry
Alvotech and marketing partner Teva have confirmed that their AVT04 proposed ustekinumab biosimilar rival to Stelara has been filed with the US FDA, ahead of a key patent expiry later this year.
Infringement Order Blocks Viatris’ US Symbicort Rival Until July 2023
After a string of victories, Viatris has fallen to AstraZeneca’s US Symbicort intellectual property, pushing back its planned generic launch by half a year.